217 related articles for article (PubMed ID: 19622583)
1. Adjuvant trastuzumab induces ventricular remodeling despite aerobic exercise training.
Haykowsky MJ; Mackey JR; Thompson RB; Jones LW; Paterson DI
Clin Cancer Res; 2009 Aug; 15(15):4963-7. PubMed ID: 19622583
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
3. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
5. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
[TBL] [Abstract][Full Text] [Related]
7. Heart remodeling induced by adjuvant trastuzumab-containing chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2: a prospective study.
Piotrowski G; Gawor R; Bourge RC; Stasiak A; Potemski P; Gawor Z; Nanda NC; Banach M
Pharmacol Res; 2013 Dec; 78():41-8. PubMed ID: 24171840
[TBL] [Abstract][Full Text] [Related]
8. [Cardiotoxicity of trastuzumab of significance in the adjuvant treatment of breast cancer].
Menke-van der Houven van Oordt CW; Fliervoet HJ; Mandigers CM; van Spronsen DJ
Ned Tijdschr Geneeskd; 2008 Jan; 152(3):158-63. PubMed ID: 18271465
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
[TBL] [Abstract][Full Text] [Related]
12. Management of trastuzumab-related cardiac dysfunction.
Carver JR
Prog Cardiovasc Dis; 2010; 53(2):130-9. PubMed ID: 20728700
[TBL] [Abstract][Full Text] [Related]
13. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
[TBL] [Abstract][Full Text] [Related]
14. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule.
Baselga J; Carbonell X; Castañeda-Soto NJ; Clemens M; Green M; Harvey V; Morales S; Barton C; Ghahramani P
J Clin Oncol; 2005 Apr; 23(10):2162-71. PubMed ID: 15800309
[TBL] [Abstract][Full Text] [Related]
16. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
17. [Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients].
Zhou NN; Teng XY; Liu DG; Xu R; Guan ZZ
Ai Zheng; 2008 Dec; 27(12):1307-9. PubMed ID: 19079999
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study.
Wadhwa D; Fallah-Rad N; Grenier D; Krahn M; Fang T; Ahmadie R; Walker JR; Lister D; Arora RC; Barac I; Morris A; Jassal DS
Breast Cancer Res Treat; 2009 Sep; 117(2):357-64. PubMed ID: 19082707
[TBL] [Abstract][Full Text] [Related]
19. Time Trends of Left Ventricular Ejection Fraction and Myocardial Deformation Indices in a Cohort of Women with Breast Cancer Treated with Anthracyclines, Taxanes, and Trastuzumab.
Tan TC; Bouras S; Sawaya H; Sebag IA; Cohen V; Picard MH; Passeri J; Kuter I; Scherrer-Crosbie M
J Am Soc Echocardiogr; 2015 May; 28(5):509-14. PubMed ID: 25772019
[TBL] [Abstract][Full Text] [Related]
20. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial.
Perez EA; Suman VJ; Davidson NE; Kaufman PA; Martino S; Dakhil SR; Ingle JN; Rodeheffer RJ; Gersh BJ; Jaffe AS
J Clin Oncol; 2004 Sep; 22(18):3700-4. PubMed ID: 15365066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
